Slavica Biochem

Welcome to the homepage of the Slavica Biochem – a registered subsidiary of HTDS Medical. Slavica BioChem comprises a group of research scientists who have teamed up with a goal of performing cutting edge research in the field of neurological impairments.

The IBISSgroup is a team of neurophysiologists and molecular biologists working on neurological impairments in Multiple Sclerosis (MS) and Traumatic Brain Injury (TBI). The primary focus of IBISSgroup is to investigate novel therapeutic approaches in treatment of these disorders of the CNS (central nervous system).

The effectiveness of the new therapies was shown in experimental animals and has yet to be proven in humans, hence the current results have to be considered as experimental and not definite. The therapeutic substances tested in the animal model of MS and TBI include existing in-use drugs, such as RIBAVIRIN and TIAZOFURIN.

RIBAVIRIN is already FDA approved drug used in human clinical practice as antiviral drug (VIRAZOLE®) and is very successful in treatment of Respiratory Syncytial Virus (RSV) in children, hepatitis C, SARS and HIV.

TIAZOFURIN was granted the orphan-drug status by FDA for the Treatment of Chronic Myelogenous Leukemia (CML). It is also in Phase II of clinical trials of anticancer drugs.

IBISSgroup is conducting a thorough research aimed to enhance and modify these substances to be used in MS and TBI treatment.

IBISSgroup is associated with the Department of Neurobiology, Institute for Biological Research “Sinisa Stankovic”, University of Belgrade, Belgrade, Serbia. The leader of the IBISSgroup is professor dr Mirjana Stojiljkovic, a well known scientist who also acts as Medical Advisor of HTDS Medical.